These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 26656202)
1. Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Muehe AM; Feng D; von Eyben R; Luna-Fineman S; Link MP; Muthig T; Huddleston AE; Neuwelt EA; Daldrup-Link HE Invest Radiol; 2016 Apr; 51(4):221-227. PubMed ID: 26656202 [TBL] [Abstract][Full Text] [Related]
2. Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI. Nguyen KL; Yoshida T; Kathuria-Prakash N; Zaki IH; Varallyay CG; Semple SI; Saouaf R; Rigsby CK; Stoumpos S; Whitehead KK; Griffin LM; Saloner D; Hope MD; Prince MR; Fogel MA; Schiebler ML; Roditi GH; Radjenovic A; Newby DE; Neuwelt EA; Bashir MR; Hu P; Finn JP Radiology; 2019 Dec; 293(3):554-564. PubMed ID: 31638489 [TBL] [Abstract][Full Text] [Related]
3. Hemodynamic safety and efficacy of ferumoxytol as an intravenous contrast agents in pediatric patients and young adults. Ning P; Zucker EJ; Wong P; Vasanawala SS Magn Reson Imaging; 2016 Feb; 34(2):152-8. PubMed ID: 26518061 [TBL] [Abstract][Full Text] [Related]
4. MRI with ferumoxytol: A single center experience of safety across the age spectrum. Nguyen KL; Yoshida T; Han F; Ayad I; Reemtsen BL; Salusky IB; Satou GM; Hu P; Finn JP J Magn Reson Imaging; 2017 Mar; 45(3):804-812. PubMed ID: 27480885 [TBL] [Abstract][Full Text] [Related]
5. Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol. Luhar A; Khan S; Finn JP; Ghahremani S; Griggs R; Zaritsky J; Salusky I; Hall TR Pediatr Radiol; 2016 Aug; 46(9):1332-40. PubMed ID: 27059620 [TBL] [Abstract][Full Text] [Related]
6. Safety of ferumoxytol in children undergoing cardiac MRI under general anaesthesia. Wise-Faberowski L; Velasquez N; Chan F; Vasanawala S; McElhinney DB; Ramamoorthy C Cardiol Young; 2018 Jul; 28(7):916-921. PubMed ID: 29848399 [TBL] [Abstract][Full Text] [Related]
7. What Does the Boxed Warning Tell Us? Safe Practice of Using Ferumoxytol as an MRI Contrast Agent. Varallyay CG; Toth GB; Fu R; Netto JP; Firkins J; Ambady P; Neuwelt EA AJNR Am J Neuroradiol; 2017 Jul; 38(7):1297-1302. PubMed ID: 28495944 [TBL] [Abstract][Full Text] [Related]
8. Brain Iron Assessment after Ferumoxytol-enhanced MRI in Children and Young Adults with Arteriovenous Malformations: A Case-Control Study. Iv M; Ng NN; Nair S; Zhang Y; Lavezo J; Cheshier SH; Holdsworth SJ; Moseley ME; Rosenberg J; Grant GA; Yeom KW Radiology; 2020 Nov; 297(2):438-446. PubMed ID: 32930651 [TBL] [Abstract][Full Text] [Related]
9. Ferumoxytol as an off-label contrast agent in body 3T MR angiography: a pilot study in children. Ruangwattanapaisarn N; Hsiao A; Vasanawala SS Pediatr Radiol; 2015 Jun; 45(6):831-9. PubMed ID: 25427433 [TBL] [Abstract][Full Text] [Related]
10. Brand ferumoxytol vs. generic ferumoxytol comparison across two dosing regimens: a cardiac MRI image quality study. Dasi A; Kring DN; Selvaraj B; Morgan P; Gerity C; Morgan EE; Krishnamurthy R; Krishnamurthy R Pediatr Radiol; 2023 Dec; 53(13):2622-2632. PubMed ID: 37837456 [TBL] [Abstract][Full Text] [Related]
11. Differentiation of benign and malignant lymph nodes in pediatric patients on ferumoxytol-enhanced PET/MRI. Muehe AM; Siedek F; Theruvath AJ; Seekins J; Spunt SL; Pribnow A; Hazard FK; Liang T; Daldrup-Link H Theranostics; 2020; 10(8):3612-3621. PubMed ID: 32206111 [TBL] [Abstract][Full Text] [Related]
12. A case of severe anaphylactic reaction after administration of diagnostic-dose ferumoxytol in a pediatric patient. Ekladious F; Saul D Pediatr Radiol; 2024 Aug; 54(9):1553-1555. PubMed ID: 38907841 [TBL] [Abstract][Full Text] [Related]
13. Safety of Off-Label Use of Ferumoxtyol as a Contrast Agent for MRI: A Systematic Review and Meta-Analysis of Adverse Events. Ahmad F; Treanor L; McGrath TA; Walker D; McInnes MDF; Schieda N J Magn Reson Imaging; 2021 Mar; 53(3):840-858. PubMed ID: 33098154 [TBL] [Abstract][Full Text] [Related]
14. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Lu M; Cohen MH; Rieves D; Pazdur R Am J Hematol; 2010 May; 85(5):315-9. PubMed ID: 20201089 [TBL] [Abstract][Full Text] [Related]
15. Can Ferumoxytol be Used as a Contrast Agent to Differentiate Between Acute and Chronic Inflammatory Kidney Disease?: Feasibility Study in a Rat Model. Budjan J; Neudecker S; Schock-Kusch D; Kraenzlin B; Schoenberg SO; Michaely HJ; Attenberger UI Invest Radiol; 2016 Feb; 51(2):100-5. PubMed ID: 26352750 [TBL] [Abstract][Full Text] [Related]
16. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Stabi KL; Bendz LM Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905 [TBL] [Abstract][Full Text] [Related]
17. Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging. Nguyen KL; Park EA; Yoshida T; Hu P; Finn JP J Cardiovasc Magn Reson; 2017 Dec; 19(1):106. PubMed ID: 29284494 [TBL] [Abstract][Full Text] [Related]
18. Safety of ferumoxytol in patients with anemia and CKD. Singh A; Patel T; Hertel J; Bernardo M; Kausz A; Brenner L Am J Kidney Dis; 2008 Nov; 52(5):907-15. PubMed ID: 18824288 [TBL] [Abstract][Full Text] [Related]
19. Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: first case series. Hassan N; Cahill J; Rajasekaran S; Kovey K Ann Pharmacother; 2011 Dec; 45(12):e63. PubMed ID: 22116997 [TBL] [Abstract][Full Text] [Related]
20. Ferumoxytol as an intraprostatic MR contrast agent for lymph node mapping of the prostate: a feasibility study in non-human primates. Sankineni S; Smedley J; Bernardo M; Brown AM; Johnson L; Muller B; Griffiths GL; Kobayashi H; Rais-Bahrami S; Pinto PA; Wood BJ; Keele B; Choyke PL; Turkbey B Acta Radiol; 2016 Nov; 57(11):1396-1401. PubMed ID: 26013022 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]